CellaVision AB
STO:CEVI
CellaVision AB
Total Equity
CellaVision AB
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CellaVision AB
STO:CEVI
|
Total Equity
kr815.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Total Equity
kr10.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
S
|
Surgical Science Sweden AB
STO:SUS
|
Total Equity
kr4.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Getinge AB
STO:GETI B
|
Total Equity
kr33B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Total Equity
kr8.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Total Equity
kr699.4m
|
CAGR 3-Years
68%
|
CAGR 5-Years
47%
|
CAGR 10-Years
34%
|
|
CellaVision AB
Glance View
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
See Also
What is CellaVision AB's Total Equity?
Total Equity
815.7m
SEK
Based on the financial report for Dec 31, 2024, CellaVision AB's Total Equity amounts to 815.7m SEK.
What is CellaVision AB's Total Equity growth rate?
Total Equity CAGR 10Y
18%
Over the last year, the Total Equity growth was 14%. The average annual Total Equity growth rates for CellaVision AB have been 15% over the past three years , 19% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet